10-Q: Dyadic International Faces Going Concern Doubt Amidst Q2 2026 Results

Dyadic International reported a net loss of $2.12 million for Q2 2026, with significant concerns remaining about its ability to continue as a going concern.

Summary

• Dyadic International reported a net loss of $2,123,884 for the three months ended June 30, 2026, and $4,078,567 for the six months ended June 30, 2026.
• The company continues to face substantial doubt regarding its ability to continue as a going concern, primarily due to its history of net losses and negative cash flows.
• Total revenue for the three months ended June 30, 2026, was $961,138, a slight decrease of 0.6% from the prior year, while six-month revenue increased by 52.3% to $2,072,094.
• Research and development expenses decreased significantly, by 47.2% for the quarter and 28.1% for the six months, reflecting a reduction in internal research initiatives.
• General and administrative expenses increased by 17.6% for the quarter and 13.6% for the six months, driven by rebranding, business development, and legal/accounting costs.
• The company has received full funding for the Gates Foundation Grant and is advancing programs with CEPI/FBS and NIAID.
• Dyadic is pursuing multiple strategies to mitigate going concern risks, including capital raises, grant applications, commercial pilot sales, and licensing revenue.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the continued substantial doubt about the company's ability to continue as a going concern, despite some progress in grant funding and collaborations.

Positives

• Grant revenue increased significantly, with $334,071 more in the three-month period and $610,965 more in the six-month period, primarily from CEPI and Gates Foundation grants.
• The company has received the full $3,092,136 from the Gates Foundation Grant.
• Progress in commercial sales and product shipments, including initial pilot sales of recombinant transferrin and growth factors for cultivated-meat applications.
• Proliant has begun commercialization of Albufree DX and plans to expand the Albufree portfolio, positioning Dyadic for future royalties.
• Inzymes confirmed initial commercial sales of non-animal bovine chymosin, with a second product in development.
• Fermbox Bio has scaled commercialization and received initial orders for recombinant DNase I and human transferrin.
• Pilot-scale process improvements increased recombinant human transferrin productivity by approximately 80%.
• Demonstrated rapid response capability by producing BDBV antigens in approximately 15 days.

Negatives

• A net loss of $2,123,884 was reported for the three months ended June 30, 2026, and $4,078,567 for the six months ended June 30, 2026.
• Substantial doubt exists regarding the company's ability to continue as a going concern within 12 months from the issuance date of the financial statements.
• Total revenue for the three months ended June 30, 2026, decreased by 0.6% compared to the prior year.
• Cost of revenue increased significantly by 60.4% for the quarter and 94.9% for the six months.
• General and administrative expenses increased by 17.6% for the quarter and 13.6% for the six months.
• Cash and cash equivalents, restricted cash, and investment securities decreased to $4.8 million as of June 30, 2026, from $8.6 million as of December 31, 2025.
• Net cash used in operating activities was $3.8 million for the six months ended June 30, 2026.

Risks

• Substantial doubt about the company's ability to continue as a going concern within 12 months from the issuance date of the financial statements.
• The company's success depends on its ability to raise capital to finance developmental efforts.
• Failure to comply with Nasdaq listing standards could lead to delisting, adversely affecting liquidity and market price.
• Any capital raise could be highly dilutive to existing investors.
• There is no certainty that the company will be able to execute its mitigation plans (capital raises, grant funding, commercial sales, licensing) in a timely fashion or at all.
• The loss of business from one or a combination of the company's significant customers could adversely affect its operations.
• The loss of one or a combination of the company's CROs could adversely affect its operations.
• Protracted litigation and/or an unfavorable resolution of one or more proceedings could have a material adverse effect on the company's financial condition.

Future Outlook

The company expects to continue incurring losses and negative cash flows as it develops its platforms and products. Success is dependent on its ability to commercialize technologies, generate revenue through sublicensing, and raise additional capital. Management is pursuing several strategies to mitigate going concern risks, including capital raises, grant funding, commercial pilot sales, and licensing revenue.

Management Comments

• The rebranding to Dyadic Applied BioSolutions marks a strategic transition from a research-driven organization to a commercially focused enterprise, better reflecting the emphasis on delivering applied biotechnology solutions.
• Management has concluded that there is substantial doubt about the Company's ability to continue as a going concern within 12 months from the issuance date of the financial statements.
• The Company believes that substantial doubt exists regarding its ability to continue as a going concern for at least 12 months from the date of issuance of the Companys condensed financial statements.
• The Company was in compliance with its covenants with respect to the Convertible Notes as of June 30, 2026.

Industry Context

StockSavvy.ai notes that Dyadic operates in the competitive biotechnology sector, focusing on protein production platforms. The company's strategy to focus on non-therapeutic proteins aims to reduce regulatory complexity and accelerate time to revenue, a common approach for companies seeking to monetize platform technologies before or alongside therapeutic development.

Comparison to Industry Standards

• The company's net loss of $4.08 million for the first six months of 2026 and accumulated deficit of $97.53 million are significant, indicating a high burn rate typical of early-stage biotechnology companies, but also a critical concern for sustainability.
• While grant funding from organizations like the Gates Foundation and CEPI is a positive sign of external validation, it is not a substitute for sustainable commercial revenue.
• The company's reliance on convertible notes, particularly those with related parties, and the ongoing need for capital raises are common in the industry but highlight financial vulnerability.
• The focus on animal-free protein production aligns with growing market trends for sustainable and ethical sourcing in food and industrial applications, a segment where competitors are also emerging.

Legal Proceedings

• The company is not currently involved in any litigation that it believes could have a materially adverse effect on its financial condition or results of operations.
• From time to time, the Company is subject to legal proceedings, asserted claims and investigations in the ordinary course of business, including commercial claims, employment and other matters, which management considers immaterial, individually and in the aggregate.

Related Party Transactions

• The company issued $6,000,000 of 8.0% Senior Secured Convertible Promissory Notes, with purchasers including immediate family members and family trusts related to CEO Mark Emalfarb.
• On September 15, 2025, a trust for the benefit of CEO Mark Emalfarb was added as a Secured Party after his purchase and assignment of a $1,000,000 Note.
• Accrued interest on Convertible Notes includes amounts for related parties: $41,800 as of June 30, 2026, and $21,800 as of June 30, 2025.
• Joseph Hazelton, President and Chief Operating Officer, purchased 26,000 shares of common stock in the August 1, 2025 offering.

Stakeholder Impact

• Shareholders face continued dilution risk from potential capital raises and the ongoing going concern issue.
• Investors may lose the entire value of their investment if the company becomes insolvent.
• Employees and collaborators may experience uncertainty regarding the company's long-term viability.
• Creditors and suppliers may face risks if the company cannot meet its financial obligations.

Next Steps

• Continue to pursue securing additional capital through equity offerings or other financing means.
• Apply for grant funding from various organizations.
• Execute on commercial pilot sales, with recognized sales revenues anticipated to begin in the second half of 2026.
• Obtain licensing revenue from interested parties.
• Advance Gates Foundation-funded RSV and malaria monoclonal antibody programs.
• Continue C1 development with CEPI/Fondazione Biotecnopolo di Siena (FBS) and NIAID-supported preclinical evaluation.
• Scale commercialization and pursue initial orders for recombinant proteins.
• Pursue potential monoclonal antibody programs through the European Vaccines Hub/FBS ecosystem.

Key Dates

Recommendation

The persistent substantial doubt about the company's ability to continue as a going concern, coupled with increasing net losses and rising costs, presents a significant risk to investors. While there are positive developments in grant funding and commercialization efforts, these are not yet sufficient to offset the financial challenges. The potential for highly dilutive capital raises further diminishes the outlook for existing shareholders.

Keywords

biotechnology, protein production, microbial platforms, Dapibus, C1 platform, life sciences, food and nutrition, industrial bioprocessing